BrainU

BrainU operates at the intersection of neurotechnology, digital health, AI, mental health, and wellness. Its portfolio suggests a broader application strategy than a single-purpose digital therapeutic: CAI and CAI+ appear to address core brain or mental-health use cases, while VET CAI extends the concept into veterinary care and NeuroKIDS targets children. BrainLog, MENTALade, and ST1 add further product identities, although their specific functions are not publicly detailed enough to determine whether they are software products, assessment tools, clinical services, or supporting platforms. BrainU’s apparent differentiator is portfolio breadth across human, child, and veterinary applications rather than demonstrated scale in one clearly defined category. The company’s positioning is therefore best characterized as an emerging, multi-application brain-health technology business.

BrainU’s available history indicates development across multiple product concepts and continued financing activity between 2019 and 2024. The 2019 TIPS-related event involving Entels and a separate investment-attraction event involving Credit Guarantee Fund mark the earliest visible financing milestones. Investment-attraction activity associated with K-Ground Fund in 2023 and Solid Investment Association in 2024 suggests that the company continued pursuing external capital after its initial development period. The portfolio also appears to have expanded beyond a single brain-health application, with named products covering general use cases, veterinary care, children, mental-health applications, and other brain-related tools. There is no reported hiring news, while recent layoffs are not indicated. Consequently, BrainU’s trajectory can be described as product- and financing-oriented rather than quantitatively validated. The main inflection points are the 2019 initial financing activity, the 2023 follow-on investment event, and the 2024 financing event, with the commercial impact of each remaining unclear.